Objective: To analyze the clinical efficacy of intrathyroid thymic carcinoma (ITTC). Methods: This study retrospectively analyzed the clinical data of 21 patients with ITTC diagnosed and treated at the First Affiliated Hospital of Zhengzhou University from January 2018 to July 2023, including 9 males and 12 females, with a median age of 52 years (40-60 years old). Results: There is a correlation between the maximum diameter of the tumor (≥40 mm) and lymph node metastasis (P=0.044). Seventeen patients received surgical treatment, and 4 patients only received chemotherapy. During the follow-up period, a total of 4 patients experienced death or progression, with a 2-year mortality or progression free survival rate of 74.8%. Conclusions: The prognosis of ITTC is good, and surgical treatment is the preferred treatment option, lymph node metastasis is significantly correlated with prognosis. The radiotherapy and chemotherapy of ITTC need to be determined based on the patient's condition.
目的： 分析甲状腺内胸腺癌（ITTC）临床疗效。 方法： 回顾性分析2018年1月至2023年7月郑州大学第一附属医院诊疗的21例ITTC患者的临床资料，总结临床疗效。其中男9例，女12例，中位年龄52岁（40~60岁）。 结果： 肿瘤最大径（≥40 mm）与淋巴结转移有相关性（P=0.044）。17例患者接受手术治疗，4例仅行化疗。随访期间，共有4例患者出现死亡或进展，2年无死亡或进展生存率为74.8%。 结论： ITTC的预后良好，手术治疗是首选的治疗方案，淋巴结转移与预后显著相关。ITTC的放化疗需要根据患者的病情来确定。.